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Dear Editor,
The myeloproliferative disorders (MPDs) constitute 
a subcategory of chronic myeloid disorders and in-
clude chronic myeloid leukemia (CML), essential 
thrombocytemia (ET), polycythemia vera (PV) and 
myelofibrosis (MF). In 1960, the discovery of the 
Philadelphia  chromosome  (Ph)  became  a  corner-
stone in CML treatment and led to the development 
of  moleculary  targeted  therapy.  Recently,  an  ac-
quired mutation in the Janus kinase 2 (JAK2) gene 
has been discovered in nearly all patents with PV 
and approximately half of the patients with primary 
MF and ET. Subsequently, the mutation has been 
demonstrated  in  atypical  MPDs  (chronic  neutro-
philic leukemia, unclassified), de novo myelodys-
plastic syndrome or acute myeloid leukemia.1 It has 
been hoped that targeted inhibition of JAK2V617F 
should achieve similar disease control as thyrosine 
kinases has produced in CML.
A  gain-of-function  mutation  at  codon  617 
(V617F) of the JAK2 gene causes constitutive acti-
vation of the JAK-STAT pathway which in turn leads 
to uncontrolled hematopoietic cell proliferation.2 In 
mice, JAK2V617F induces a PV-like disease with 
erythrocytosis,  low  serum  erythropoietin  (Epo) 
level, splenomegaly, extramedullary hematopoiesis, 
megakaryocytic  hyperplasia,  and  anemia.2,  3 Tef-
feri suggested that JAK2V617F mutation probably 
leads to a PV-weighted MPD phenotype.1
Jelinek  et  al.  reported  no  mutated  cases  for 
JAK21849G>T in 99 CML patients, including 55 
imatinib-resistant subjects.4 Similarly, Bock et al. 
did not detect JAK2 mutation in 5 Ph+ CML patients 
in a previous report.5 In contrast with these reports, 
more recently, several cases with the coexistence of 
BCR-ABL fusion gene and JAK2V617F mutation 
in blood and bone marrow samples were reported. 
6–13 We report here a new case with concomitant 
BCR-ABL rearrangement and JAK2V617F muta-
tion, and compare our findings with those of similar 
reports.
A  58-year-old  female  patient  presented  with 
ruddy face, dizziness, flushing and pruritis. Physical 
examination was normal with no palpable spleen 
enlargement. The hematological parameters were as 
follows: white blood cells, 20.3x109/L with a dif-
ferential  count  of  83%  neutrophils;  hemoglobin, 
16.9g/dL;  hematocrite,  %56,4;  platelets  387x103/
µl. Peripheral smear revealed thrombocytosis and 
left shift of the myeloid series. Iron deficiency and 
inflammation were ruled out. The leukocyte alka-
line phosphatase (LAP) score was below 10%. Ar-
terial blood gas analysis revealed a normal oxygen 
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reference  values  [3,6  mU/mL  (4,5–33  mU/mL)]. 
Hydroxyurea and allopurinol were started for de-
creasing cell load and additionally hydration was 
supplied. Hematocrite levels were lowered as 45% 
via flebotomies.
Histopathologic examination of bone marrow 
biopsy revealed 95% cellularity, markedly increased 
myeloid  series,  decreased  blast  ratio  (<0.05),  in-
creased myeloid/erythroid ratio (5/1) and increased 
dismature  megacaryocytes.  Immünohistochemical 
staining with prussian blue revealed decreased iron 
deposits and stage 0 CML was reported in accord-
ing to reticulin fibrosis score. Abdominal ultrasound 
examination  has  no  pathologic  findings  related 
with  spleen,  liver  and  the  other  organs.  Cytoge-
netic  analysis  revealed  no  cytogenetic  abnormal-
ity. The examination of peripheral blood samples 
by using PCR revealed that BCR-ABL (P210) was 
0.01. Translocation (t 9;22) was found 8% positive 
in  FISH  study  by  using  BCR-ABL  translocation 
probe. As a part of diagnostic evaluation of MPDs, 
JAK2V617F mutation analysis was performed and 
was found to be positive in according to Rotor gen 
real time PCR analysis in peripheral blood. There-
fore, the coexistence of JAK2 mutation and Phila-
delphia chromosome (Ph+) was observed in a single 
patient. These results revealed the diagnosis of a 
myeloproliferative disease (CML/PV) and imatinib 
therapy was started at 400 mg/day.
There is a debate as to whether MPD and CML 
arise separately from each other, representing inde-
pendent development from a normal stem cell, or 
whether the Ph chromosome arises in a stem cell of 
a MPD clone.11
The unexpected hematological responses (in-
cluding  thrombocytosis),7  or  erythrocytosis,8,9 
evolving myelofibrosis,10,11 and/or persisting spleen 
enlargement,7,12 under imatinib mesylate treatment 
led some physicians to detect for JAK2 mutation in 
either peripheral blood or bone marrow. Probably, 
imatinib therapy suppresses the BCR-ABL clone, 
enabling the proliferation of JAK2V617F mutated 
cells. It is likely that the dominance of JAK2 posi-
tive clone obtain an escape effect which may ex-
plain the mechanism of bone marrow fibrosis and 
also hematological changes. Campiotti et al. have 
prospectively  detected  JAK2  mutation  positivity 
in one patient among 13 new cases of Ph+ positive 
CML.13 In contrast with other reports;7–12 after the 
partial cytogenetic response to imatinib treatment, 
JAK2  mutation  was  disappeared. Therefore,  they 
have  firstly  hypothesized  that  imatinib  treatment 
have caused the regression of CML clone, as well 
as  JAK2  mutated  cells,  and  that  JAK2  mutation 
can be acquired by Ph+ cells ,13 But in most cases, 
as described previously, imatinib mesylate therapy 
did not effect the coexisting and/or acquired JAK2 
clone,7–12 Moreover,  owing  to  a  proliferative  ad-
vantage, JAK2 mutated hematopoiesis could over-
whelm the BCR-ABL translocated hematopoiesis. 
To our knowledge, it seems more likely that there 
are  two  independent  growing  aberrant  stem  cell 
clones.
On the other hand, some patients with preex-
isting  JAK2V617F  positive  MPD  were  found  to 
have Philadelphia translocation in the literature.11,14–
16  Krämer  et  al.  showed  retrospectively  that  the 
JAK2V617F mutation was already present at ini-
tial diagnosis of BCR-ABL positive CML. And af-
ter the successful treatment of CML with imatinib, 
JAK2V617F might have been responsible for the 
development of myelofibrosis.11
Eventhough the JAK2V617F mutation has been 
excluded in a large cohort of BCR-ABL patients,4 
the present report gives evidence that the coexis-
tence of these two disease-spesific mutations is pos-
sible. Physicians have to keep in mind that unex-
pected hematological responses, evolving myelofi-
brosis, and/or persisting spleen enlargement during 
effective treatment of Ph+ CML may be caused by 
an underlying JAK2 positive hematopoietic clone.
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